Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + mFOLFOX-6 in metastatic colorectal cancer
NCT00862784Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2009
- Primary completion
- Apr 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in metastatic colorectal cancer (mCRC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival up to 28.1 months. Started Apr 2009; status: completed.
02
Drugs
ramucirumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00862784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862784.